The clinical application of a low-profile stent for symptomatic intracranial atherosclerotic stenosis in the middle cerebral artery: a retrospective study of the Atlas stent Authors: Wenyan Xu, Xu Guan, Fangfang Guo, Chaoyang Zhang, Yiran Meng, Hua Jin, Zhijun Liu, Yang Bian, Xiaohui Wang, Rongju Zhang, Xinfeng Liu, Zhihua Du, Xing Chen, Jun Wang, Xiangyu Cao, Bin Lv Published: 2026 ABSTRACT AbstractBackgroundIntracranial atherosclerotic stenosis (ICAS) is a major cause of ischemic stroke, conferring high recurrence risk especially among East Asian populations. Landmark trials revealed limitations of Wingspan stenting, including restenosis concerns. The low-profile, flexible Neuroform Atlas stent, initially designed for intracranial aneurysms, may be suitable for tortuous intracranial vessels, yet its real-world evidence for middle cerebral artery (MCA)-segment symptomatic ICAS (sICAS) remains insufficient. This study aimed to evaluate the safety and efficacy of the Neuroform Atlas stent for treating sICAS involving the MCA M1-M2 segment and explore the clinical value of individualized balloon dilation strategies.MethodsA retrospective analysis was conducted on 22 consecutive patients with severe sICAS (70–99% stenosis) in the MCA M1-M2 segment, who were treated with the Neuroform Atlas stent at our center between November 2021 and June 2025. The primary endpoints were technical success rate, perioperative complications, and improvement in vascular stenosis immediately after the procedure and at the 6-month follow-up, including the incidence of in-stent restenosis. An exploratory analysis was performed on cases with different balloon dilation strategies.ResultsThe technical success rate was 100% in all 22 cases, with no perioperative stroke or death. The mean preprocedural stenosis rate was 80.86%±9.82%, which decreased immediately after the procedure to 32.34%±10.36% (P<0.01). Among the 19 patients who completed imaging follow-up, the mean residual stenosis rate at 6 months was 38.43%±21.39%, showing no statistically significant difference compared with the immediate postprocedural value (P>0.05). The restenosis rate was 10.53% (2/19), with both cases being asymptomatic and occurring in Mori type B or C lesions. The multiple balloon dilation group had a higher baseline stenosis degree, but no statistically significant difference was observed between the two groups in either the immediate postprocedural residual stenosis rate or the 6-month residual stenosis rate.ConclusionsThe Neuroform Atlas stent is safe and effective for treating sICAS in the MCA M1-M2 segment. An individualized balloon predilation strategy can optimize immediate lumen reconstruction for complex lesions without significantly affecting long-term patency. The inherent complexity of the lesion itself may be associated with postoperative restenosis.Keywords: Symptomatic intracranial atherosclerotic stenosis (sICAS), endovascular treatment, Neuroform Atlas stent, balloon angioplasty Introduction Ischemic stroke remains a disease with high global incidence, characterized by high rates of recurrence and disability. It is a leading cause of disability-adjusted life year (DALY) loss and imposes a substantial economic burden on society (1-3). Intracranial atherosclerotic stenosis (ICAS) is a major etiology of stroke worldwide, with a particularly higher disease burden in East Asian populations and non-White groups in the United States. ICAS significantly increases the risk of stroke recurrence, with an annual recurrence rate exceeding 20% for stenoses of ≥70% (4). The 2005 Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial demonstrated that medical therapy alone was insufficient for optimal control of stroke recurrence (5). Consequently, exploring endovascular treatment for ICAS has become a research focus in the field of neurointervention, with symptomatic ICAS (sICAS) being the primary target for clinical intervention. In 2005, the Wingspan stent entered clinical trials as the world’s first dedicated stent for ICAS (6,7). Early studies—the SAMMPRIS (8) and VISSIT (9) trials—were terminated prematurely due to safety concerns. Subsequent research, including the WEAVE trial and the CASSISS study with its follow-up data, indicated that the safety profile of the Wingspan stent could be improved through stringent patient selection and operation by experienced physicians (10,11). However, its 1-year follow-up restenosis rate was reported as 17.6% (12), and it showed no benefit over medical therapy alone (13). Thus, limitations remain regarding the Wingspan stent’s restenosis rate and long-term clinical benefit. Endovascular treatment for ICAS lesions often faces anatomical challenges, such as small vessel diameter, tortuous pathways, and abundant perforating arteries. The Neuroform Atlas stent, featuring a low-profile and high-flexibility design delivered via a slender 0.017-inch microcatheter system, is particularly suitable for navigation and deployment in the delicate and tortuous intracranial arteries. Previous clinical studies have demonstrated its feasibility and safety in treating ICAS (14-16). To further evaluate the efficacy of the Atlas stent for distal intracranial vascular lesions, this retrospective study analyzed the clinical data of 22 patients with sICAS in the middle cerebral artery (MCA) M1-M2 segment treated with the Atlas stent. The aim was to provide evidence to inform clinical decision-making regarding the application of this technology in such delicate vascular territories. We present this article in accordance with the STROBE reporting checklist (available at https://qims.amegroups.com/article/view/10.21037/qims-2026-1542/rc). Methods Patient population A retrospective analysis was conducted on 22 consecutive patients with sICAS in the MCA M1-M2 segment. All patients were hospitalized in the Department of Neurology at the First Medical Center of the Chinese PLA General Hospital between November 2021 and June 2025 and were treated with the Neuroform Atlas stent. The presence of intracranial vascular stenosis, with a degree ranging from 70% to 99%, was confirmed in all cases by digital subtraction angiography (DSA) and three-dimensional (3D) reconstruction. The sample size was determined by all consecutive eligible patients treated within the predefined study period; no formal pre-study power calculation was performed. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. The study was approved by the Ethics Committee of Chinese PLA General Hospital (No. S2022-357-01), and the requirement for written informed consent was waived due to its retrospective nature. Inclusion and exclusion criteria The inclusion criteria were as follows: (I) sICAS with severe stenosis (70–99%) of the MCA; (II) persistent transient ischemic attack (TIA), non-disabling ischemic stroke, or progressive stenosis despite 90 days of optimized medical therapy (OMT). OMT was defined as dual antiplatelet therapy (DAPT), intensive statin therapy [low-density lipoprotein cholesterol (LDL-C) <1.8 mmol/L], together with blood pressure control, glycemic control, smoking cessation, and lifestyle intervention; (III) evidence of hypoperfusion in the territory supplied by the stenotic artery, demonstrated by computed tomography perfusion (CTP) or magnetic resonance imaging (MRI) perfusion imaging, with a reduction of ≥30% on the affected side compared to the contralateral healthy side. The exclusion criteria were as follows: (I) non-sICAS, or stenosis caused by other etiologies such as confirmed or suspected vasculitis or arterial dissection; (II) acute ischemic stroke within the preceding 2 weeks; (III) preoperative modified Rankin Scale (mRS) score ≥3; (IV) presence of intracranial tumors; (V) arteriovenous malformation (AVM) within the region of the stenotic vessel. Data collection All clinical and imaging data were retrieved retrospectively from our institutional electronic medical records and angiography archive system. We collected patients’ baseline demographic data including age, sex, height, and weight, as well as pre-admission antiplatelet therapy regimens. Baseline neurological function at initial presentation was recorded using the National Institutes of Health Stroke Scale (NIHSS). We also fully documented atherosclerotic risk factors such as hypertension, diabetes, hyperlipidemia, coronary artery disease, and prior stroke history. Detailed lesion information involving stenosis site, stenosis percentage, and Mori classification was recorded. Preoperative clinical status was evaluated via mRS scores, and we clarified whether the index symptomatic event was TIA or ischemic stroke. Moreover, intraoperative procedural parameters, perioperative adverse complications, 6-month follow-up mRS scores, and angiographic data used to calculate the 6-month in-stent restenosis rate were all extracted and sorted out. All raw data were independently reviewed and double-checked by two experienced neurologists to ensure the integrity and reliability of the whole dataset. Potential selection and information bias inherent to retrospective chart review were minimized by strict adherence to predefined eligibility criteria. Assessment and procedural methods Assessment methods The occurrence of adverse events, including stroke and death, was evaluated immediately post-procedure, at 30 days, and at 6 months post-procedure. Technical success was defined as the successful delivery and deployment of the stent at the target lesion with a residual stenosis of <50% on final angiography. In-stent restenosis was defined as a stenosis of ≥70% at follow-up imaging. The morphology of the stenotic lesion was assessed using the Mori classification (17): type A refers to a concentric or moderately eccentric stenosis with a length of <5 mm; type B refers to a severely eccentric stenosis with a length of 5–10 mm; type C refers to a stenosis with a length of >10 mm and/or a severe angulation (>90°). All stenosis rates were measured on DSA images at the following predefined time points: T0 was the stenosis rate in the target artery prior to stent placement; T1 was the stenosis rate immediately after the stent placement procedure; T2 was the stenosis rate at the 6-month follow-up after stent placement. Neurological symptoms were assessed using the mRS and the NIHSS. Exploratory comparison of different balloon dilation strategies An exploratory comparative analysis was performed based on the number of intraoperative balloon dilations. Patients were divided into a single dilation group (underwent balloon dilation once) and a multiple dilation group (underwent balloon dilation ≥2 times). Lesion characteristics, degree of stenosis improvement, and clinical outcome indicators were compared between the two groups to assess the safety and efficacy of the different balloon dilation strategies. Preoperative preparation All patients received DAPT for at least 5 days prior to the procedure, consisting of aspirin combined with either clopidogrel or ticagrelor. Therapy was guided by thromboelastography (TEG) to ensure adequate antiplatelet response, defined as an aspirin inhibition rate >70% and a clopidogrel inhibition rate >30%. For patients who did not meet these criteria, clopidogrel was switched to ticagrelor. Concurrent medical management included blood pressure control (systolic blood pressure <140 mmHg), glycemic control for diabetic patients, lipid-lowering therapy for those with hyperlipidemia, smoking cessation, and dietary modification. Intraoperative procedure All procedures were performed under general anesthesia with the patient in the supine position. Vascular access was routinely obtained via the femoral artery with a 6-F or 8-F sheath (Cordis, Miami Lakes, FL, USA). Systemic heparinization was achieved with an initial bolus of 50 U/kg, followed by a maintenance dose of 1,250 U/h. A 6-F or 8-F guiding catheter (Cordis) was positioned in a straight segment of the internal carotid artery or vertebral artery. For patients with tortuous vascular anatomy, a 6-F Navien intermediate catheter (Medtronic Neurovascular, Minneapolis, MN, USA) was introduced through the guiding catheter, with its tip positioned near the target artery. A Synchro-14 microguidewire (Stryker, Portage, MI, USA) was shaped at its tip and used to navigate an SL-10 microcatheter (Stryker) across the stenotic segment, placing the microcatheter tip distal to the stenosis. The microguidewire was then exchanged for a Transend 300 guidewire (Boston Scientific, Marlborough, MA, USA), which was positioned distally in the responsible vessel, after which the microcatheter was withdrawn. The balloon catheter for dilation was selected based on the lesion length and vessel diameter. For complex lesions, a staged, multi-step balloon dilation strategy was employed. The diameter of the final balloon used was approximately 80% of the reference vessel diameter. Under roadmap guidance, the balloon was advanced slowly over the exchange wire to the stenosis and inflated, with the inflation maintained for 10–15 seconds. The balloon was then deflated and withdrawn, and angiography was performed to assess the improvement in stenosis. The SL-10 microcatheter was advanced over the exchange wire and positioned distal to the stenosis. The exchange wire was then withdrawn. The Neuroform Atlas stent was delivered through the SL-10 microcatheter, precisely positioned across the stenotic lesion, and deployed. Final angiography was performed to evaluate the result. DAPT was continued for at least 6 months postoperatively, followed by lifelong aspirin monotherapy. Follow-up All imaging and clinical data during hospitalization were collected by neurointerventional physicians. For follow-up, patients were scheduled for outpatient visits or telephone interviews. A DSA examination was arranged at 6 months post-procedure. If a patient declined DSA, computed tomography angiography (CTA) was performed as an alternative. Statistical analysis Statistical analyses were performed using SPSS 26.0 (IBM Corp., Armonk, NY, USA). Continuous variables with a normal distribution were presented as mean ± standard deviation. Categorical variables were presented as numbers and percentages. The stenosis rates at different time points were compared using the paired samples t-test. Non-normally distributed continuous variables were analyzed using nonparametric tests. A two-sided P value <0.05 was considered statistically significant. Subgroup analyses were exploratory: continuous variables were evaluated using descriptive comparisons only, and categorical variables were analyzed using Fisher’s exact test. Patients lost to imaging follow-up were retained for clinical outcome analysis. No key clinical variables contained missing values in the final dataset. Results Clinical characteristics A total of 22 consecutive patients met all eligibility criteria and were enrolled in this study. Of them, 21 completed long-term clinical follow-up, and 19 completed imaging follow-up. All 22 patients were included in the final clinical outcome analysis. The cohort comprised 13 males and 9 females, with an age range of 46 to 76 years and a mean age of 60.00±8.60 years. Body mass index (BMI) was <24 kg/m2 in 8 patients (36.36%), between 24 and 28 kg/m2 in 10 patients (45.45%), and ≥28 kg/m2 in 4 patients (18.18%). Vascular risk factors included hypertension in 19 patients (86.36%), diabetes mellitus in 14 patients (63.64%), and hyperlipidemia in 15 patients (68.18%). Upon admission, most patients exhibited mild neurological impairment. Specifically, 2 patients had an NIHSS score of 0, 12 patients were diagnosed with minor stroke (NIHSS: 1–4 points), 8 patients had moderate stroke (NIHSS: 5–15 points), and there were no cases of severe stroke in this cohort. All patients received DAPT upon admission, including 19 patients treated with aspirin combined with clopidogrel and 3 patients treated with aspirin combined with ticagrelor (Table 1). Table 1Baseline clinical characteristics of the study populationClinical characteristicValueAge, years60.00±8.60Sex Male13 Female9Body mass index, kg/m2 <248 (36.36) 24–2810 (45.45) >284 (18.18)Vascular risk factors Hypertension19 (86.36) Diabetes mellitus14 (63.64) Hyperlipidemia15 (68.18)Antiplatelet therapeutic regimen Aspirin combined with clopidogrel19 (86.36) Aspirin combined with ticagrelor3 (13.64)NIHSS score 0 points2 (9.09) 1–4 points12 (54.55) 5–15 points8 (36.36) ≥16 points0 (0.00)Data are presented as mean ± standard deviation, n, or n (%). NIHSS, National Institutes of Health Stroke Scale. Baseline clinical characteristics of the study population Data are presented as mean ± standard deviation, n, or n (%). NIHSS, National Institutes of Health Stroke Scale. Lesion characteristics Regarding the qualifying symptomatic events, cerebral infarction in the territory of the responsible vessel was present in 18 of 22 patients (81.82%), whereas TIA occurred in 5 patients (22.73%). One patient had both TIA and new infarction in the territory of the responsible vessel. The lesion location was the M1 segment of the MCA in 10 patients (45.45%), the M1-M2 junction in 9 patients (40.91%), and the M2 segment in 3 patients (13.64%). According to the Mori classification, lesions were categorized as type A in 6 patients (27.27%), type B in 9 patients (40.91%), and type C in 7 patients (31.82%) (Table 2). Table 2Lesion and symptom characteristicsCharacteristicn (%)Qualifying symptomatic event Cerebral infarction18 (81.82) Transient ischemic attack5 (22.73)Lesion location M1 segment10 (45.45) M1-M2 junction9 (40.91) M2 segment3 (13.64)Mori classification Type A6 (27.27) Type B9 (40.91) Type C7 (31.82) Lesion and symptom characteristics Early and long-term outcomes Stent implantation was successfully completed in all 22 patients, yielding a technical success rate of 100%. No periprocedural cerebrovascular events occurred. Long-term follow-up was completed in 21 patients (95.45%), with a mean follow-up duration of 7.23±2.30 months. Imaging follow-up (17 with DSA and 2 with CTA) was obtained for 19 patients (86.36%); the remaining 2 patients (9.09%) were followed up via telephone because they declined DSA examination. No new cerebrovascular events were reported in any of the followed-up patients. Functional assessment at the 6-month follow-up demonstrated that 14 patients (63.64%) achieved an mRS score of 0, 3 patients (13.64%) had an mRS score of 1, and 4 patients (18.18%) had an mRS score of 2. All patients attained favorable functional outcomes with mRS scores ≤2. Imaging follow-up identified in-stent restenosis in 2 of the 19 patients (10.53%), both of whom remained asymptomatic. ##Degree of stenosis improvement The preoperative stenosis rate (T0) was 80.86%±9.82%. The residual stenosis rate immediately after the procedure (T1) was 32.34%±10.36%, resulting in a net improvement (T0–T1) of 50.55%±16.13%. The difference between T1 and T0 was statistically significant (paired t-test, t=14.620, P<0.01). Among the 17 patients with DSA follow-up, the residual stenosis rate at 6 months (T2) was 38.43%±21.39%. No statistically significant difference was found between T2 and T1 (paired t-test, t=1.314, P=0.208). Cases with in-stent restenosis Two cases (Patients 15 and 20) developed in-stent restenosis. Patient 15 was a 46-year-old male with a left M1 segment lesion, classified as Mori type C. The stenosis rates were T0=80.97%, T1=33.33%, and T2=77.41%. Patient 20 was a 48-year-old male, also with a left M1 lesion, classified as Mori type B. The stenosis rates were T0=89.58%, T1=32.53%, and T2=78.93%. Comparative analysis of different balloon dilation strategies Among the 22 patients, 11 (50.00%) underwent a single balloon predilation strategy, and 11 (50.00%) underwent a multiple balloon predilation strategy. The baseline stenosis rate (T0) was slightly higher in the multiple dilation group (86.55%±9.90%) than in the single dilation group (78.45%±7.88%), suggesting that operators tended to adopt the multiple dilation strategy for lesions with greater baseline stenosis. The immediate postprocedural residual stenosis rate (T1) was 31.91%±13.06% in the multiple dilation group and 32.09%±9.18% in the single dilation group. The 6-month follow-up residual stenosis rate (T2) was 35.88%±24.72% and 40.67%±19.09%, respectively, indicating comparable outcomes between the two groups (Table 3). Table 3Changes in stenosis rates at different time points for the single and multiple balloon dilation groupsTime pointSingle dilation group (n=11)Multiple dilation group (n=11)T0, %78.45±7.8886.55±9.90T1, %32.09±9.1831.91±13.06T2, %40.67±19.0935.88±24.72T2 was available in 17 patients with DSA follow-up (single, n=8; multiple, n=9). Data are presented as mean ± standard deviation. DSA, digital subtraction angiography. Changes in stenosis rates at different time points for the single and multiple balloon dilation groups T2 was available in 17 patients with DSA follow-up (single, n=8; multiple, n=9). Data are presented as mean ± standard deviation. DSA, digital subtraction angiography. In the single dilation group, 2/11 patients (18.18%) had Mori type A lesions and 9/11 (81.82%) had Mori type B/C lesions. In the multiple dilation group, 4/11 patients (36.36%) had Mori type A lesions and 7/11 (63.64%) had Mori type B/C lesions. There was no statistically significant difference in the distribution of Mori classifications between the two groups (Fisher’s exact test). Among the 19 patients with imaging follow-up, 10 were in the multiple dilation group, and 9 were in the single dilation group. Restenosis was observed in 1/10 patients (10.00%) in the multiple dilation group and in 1/9 patients (9.09%) in the single dilation group, with no statistically significant difference in the distribution of restenosis cases between the two dilation strategies (Fisher’s exact test). Illustrative case A representative case (Patient 2) involved a 63-year-old female who presented with left-sided limb weakness. MRI of the brain confirmed a new cerebral infarction in the right frontal, temporal, and parietal lobes. Magnetic resonance angiography (MRA) indicated stenosis of the right MCA. CTP imaging demonstrated reduced cerebral blood flow/cerebral blood volume (CBF/CBV) and prolonged mean transit time/time to peak (MTT/TTP) in the right fronto-temporo-parietal region. The preoperative mRS score was 2, and the NIHSS score was 3. A Neuroform Atlas stent was successfully implanted in the M1 segment of the right MCA. A 6-month follow-up DSA showed a patent stent lumen and good distal perfusion. The follow-up mRS score was 1, and the NIHSS score was 1. No new cerebrovascular events occurred during the periprocedural period or throughout the follow-up (Figure 1). A case of sICAS in the right MCA. (A,B) Brain MRI shows a new cerebral infarction in the right parietal and temporal lobes. (C) CTP imaging demonstrates hypoperfusion in the right fronto-parieto-temporal region. (D) MRA suggests stenosis (arrow) in the M1 segment of the right MCA. (E,F) DSA reveals severe stenosis in (arrow) the M1 segment of the right MCA with poor distal vessel opacification. (G-I) Successful implantation of a Neuroform Atlas stent in the M1 segment of the right MCA. Angiography performed 10 minutes after the procedure shows a patent stent lumen and restored distal perfusion. (J-L) Follow-up DSA at 6 months post-procedure demonstrates a patent right MCA with good flow. CTP, computed tomography perfusion; DSA, digital subtraction angiography; MCA, middle cerebral artery; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; sICAS, symptomatic intracranial atherosclerotic stenosis. Discussion ICAS is a major cause of ischemic stroke, particularly prevalent in Asian populations (4). In recent years, endovascular treatment for ICAS has been a focus of research in neurointervention. With the continuous iteration of interventional devices, several stents originally designed for adjunctive coiling of intracranial aneurysms have been attempted for treating ICAS lesions, demonstrating acceptable safety and efficacy profiles (18-21). Compared to the Wingspan stent, these stents generally offer better flexibility, lower metal coverage, and higher porosity, facilitating easier deployment in tortuous vessels and posing a lower risk to perforator-rich lesions (22). The 2022 Chinese guidelines for the endovascular treatment of ICAS (23) noted that microcatheter-delivered self-expanding stents reduce procedural complexity, and the selective off-label use of such stents in ICAS treatment may be reasonable. The Neuroform Atlas stent was initially designed for coiling assistance of wide-neck intracranial aneurysms (24). Its low-profile design allows delivery via a 0.017-inch microcatheter, enabling navigation to small and tortuous intracranial vessels such as the middle cerebral and basilar arteries. The absence of a distal wire tip potentially reduces procedural risk in distal intracranial vasculature. Its hybrid-cell structure provides a balance between radial strength and flexibility, adapting better to vessel morphology and the pathological features of ICAS, such as arterial calcification and eccentric stenosis. The lower metal coverage of the Neuroform Atlas stent may attenuate neointimal hyperplasia and consequently reduce the risk of in-stent restenosis. Its good wall apposition and high porosity may lower the incidence of perforator compromise (25). Previous studies have reported that the Neuroform Atlas stent shows acceptable safety and efficacy for ICAS lesions (14-16). This retrospective study of 22 patients with sICAS in the MCA M1-M2 segment treated with the Atlas stent further confirms its safety and efficacy in these delicate and tortuous vascular segments. The technical success rate was 100%, with no periprocedural complications. The stenosis rate was significantly reduced from 80.86%±9.82% preoperatively to 32.34%±10.36% immediately post-procedure. However, our immediate postoperative residual stenosis rate (T1) was significantly lower than those reported in two other studies [47.99%±9.37% (14) and 52.2%±10.42% (16)]. We hypothesize that this difference may stem from the individualized application of balloon predilation strategy in our study. Considering the relatively modest radial force of the Atlas stent (14), a staged, more aggressive balloon predilation strategy was employed for complex lesions (Mori types B/C) with anticipated higher deployment difficulty and more severe baseline stenosis. Previous studies suggest such strategies can be used to manage calcified or eccentric stenoses to mitigate vascular injury risk (26). The subgroup analysis in our study supports this: despite a significantly higher baseline stenosis in the multiple dilation group, its immediate postoperative stenosis rate (T1) showed no statistically significant difference from that of the single dilation group. This suggests that the tailored strategy may facilitate optimal immediate lumen reconstruction in complex cases. Notably, despite the difference in immediate lumen gain, the long-term follow-up residual stenosis rate in our study (38.43%±21.39%) closely aligns with that reported by Peng et al. (14). This implies that the degree of immediate postoperative lumen gain may not have a simple linear relationship with in-stent restenosis at approximately 6 months. Regardless of whether a conservative or aggressive predilation strategy was used, a similar lumen status was achieved at mid-term follow-up. This may indicate that long-term restenosis depends more on the lesion’s inherent biological characteristics (e.g., neointimal hyperplasia response) and the stent’s long-term biocompatibility, whereas the balloon dilation strategy primarily influences the immediate mechanical outcome. This phenomenon warrants attention in future studies with larger samples. The restenosis rate in our study was 10.53% (2/19), with all cases being asymptomatic, consistent with previous reports (14-16). Both restenosis cases occurred in complex lesions (Mori types B/C), suggesting that lesion complexity may be an important associated factor for postoperative restenosis. Our study did not find an association between different balloon dilation strategies and the occurrence of restenosis, a finding potentially limited by the small sample size. Future studies are needed to distinguish the independent effects of lesion morphology and procedural strategy on restenosis. This study has several limitations, including its single-center, retrospective design, relatively small sample size, and short follow-up duration. Therefore, the aforementioned conclusions require further exploration and validation through larger-scale, prospective, multicenter randomized controlled trials. The retrospective single-center design may have introduced selection bias, as only patients receiving Atlas stenting at our institution were included, which could have led to overestimation of safety outcomes. The small sample size limited the statistical power for detecting moderate differences between subgroups. Our findings are applicable to patients with severe symptomatic MCA M1-M2 atherosclerotic stenosis who meet our inclusion criteria. The results should not be directly generalized to other intracranial segments or patients with non-atherosclerotic vasculopathy. Conclusions The present study demonstrates that the Neuroform Atlas stent is safe and effective for the treatment of sICAS involving the MCA M1-M2 segment, providing single-center consecutive-case evidence for its application in perforator-rich delicate intracranial vascular territories. Individualized intraoperative balloon predilation may optimize immediate vascular reconstruction for complex sICAS lesions, although it exerts limited influence on mid-term 6-month angiographic outcomes. The intrinsic complexity of target lesions may represent a risk factor for post-stenting restenosis. These findings may assist clinicians in developing lesion-tailored surgical strategies. Supplementary The article’s supplementary files as Acknowledgments We thank all the patients who participated in this study. We are grateful to the nurses and neurointerventional team of the Department of Neurology, Chinese PLA General Hospital for their assistance in clinical data collection and patient follow-up. We also appreciate the support from the medical imaging team for angiographic image sorting. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. The study was approved by the Ethics Committee of Chinese PLA General Hospital (No. S2022‑357‑01), and the requirement for written informed consent was waived due to its retrospective nature. Footnotes Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at https://qims.amegroups.com/article/view/10.21037/qims-2026-1542/rc Funding: None. Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-2026-1542/coif). The authors have no conflicts of interest to declare. Data Sharing Statement Available at https://qims.amegroups.com/article/view/10.21037/qims-2026-1542/dss References Associated Data Supplementary Materials The article’s supplementary files as Data Availability Statement Available at https://qims.amegroups.com/article/view/10.21037/qims-2026-1542/dss